Advertisement

Drug and Subject Influences on Measures of Depression and Negative Symptoms in Schizophrenic Patients

  • Richard Williams
  • J. Thomas Dalby
Conference paper

Abstract

Kraepelin (1) and Bleuler (2) in their seminal writings pointed out that “genuine depression” frequently occurred in schizophrenic patients and suggested that dysphoric mood arose due to awareness of the disorder and its limiting influence on their life. In the formal development of mental disorder taxonomies a preference was expressed for orthogonal dimensions which implied that pure schizophrenia excluded depression. The sheer weight of clinical observations that depressive features occurred in schizophrenic patients was tentatively acknowledged in the designation of “Schizoaffective Disorder” and DSM-III-R (3) (p. 208) notes that this “represents one of the most confusing and controversial concepts in psychiatric nosology”. Some investigators interpreted “depression-like” symptoms to be manifestations of Bleuler’s symptoms, now rediscovered and referred to as “negative symptoms”. These include affective flattening and alogia. Still others have suggested that depressed states are pharmacogenically induced (4–6). This latter idea has not received support in more recent and properly controlled investigations (7, 8).

Keywords

Beck Depression Inventory Negative Symptom Schizophrenic Patient Schizoaffective Disorder Dysphoric Mood 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kraepelin E: Dementia Praecox and Paraphrenia. Edinburgh, Livingstone, 1919.Google Scholar
  2. 2.
    Bleuler E: Dementia Praecox or the Group of Schizophrenias. New York, International Universities Press, 1950.Google Scholar
  3. 3.
    American Psychiatric Association: Diagnostic and Statistical Manual, Third Edition, Revised. Washington, D.C., APA, 1987.Google Scholar
  4. 4.
    De Alarcon R, Carney MWP: Severe depressive mood change following slow-release intramuscular fluphenazine injection. Br Med J 3: 564–567, 1969.PubMedCrossRefGoogle Scholar
  5. 5.
    Floru L, Heinrich K, Wittek F: The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Int Pharmacopsychiatry 10: 230–239, 1975.PubMedGoogle Scholar
  6. 6.
    Keskiner A: A long-term follow-up of fluphenazine enanthate treatment. Curr Ther Res 15: 305–313, 1973.PubMedGoogle Scholar
  7. 7.
    Hogarty GE, Munetz MR: Pharmacogenic depression among outpatient schizophrenic patients: A failure to substantiate. J Clin Psychopharmacol 4: 17–24, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Wistedt B, Palmstierna T: Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. J Clin Psychiatry 44: 369–371, 1983.PubMedGoogle Scholar
  9. 9.
    Crow TJ: The continuum of psychosis and its implication for the structure of the gene. Br J Psychiatry 149: 419–429, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Martin RL, Cloninger CR, Guze SB, Clayton PJ: Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 46: 9–13, 1985.PubMedGoogle Scholar
  11. 11.
    Glazew W, Prusoff B, John K, et al: Depression and social adjustment among chronic schizophrenia outpatients. J Nery Ment Dis 169: 712–717, 1981.CrossRefGoogle Scholar
  12. 12.
    Herz MI, Melville C: Relapse in schizophrenia. Am J Psychiatry 137: 801–805, 1980.PubMedGoogle Scholar
  13. 13.
    Drake RE, Gates C, Cotton PG: Suicide among schizophrenics: a comparison of attempters and completed suicides. Br J Psychiatry 149: 784–787, 1986.PubMedCrossRefGoogle Scholar
  14. 14.
    Black DW, Winokur G, Warrack G: Suicide in schizophrenia: The Iowa Record Linkage Study. J Clin Psychiatry 46: 14–17, 1985.PubMedGoogle Scholar
  15. 15.
    Loranger AW: Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 46: 157–161, 1984.CrossRefGoogle Scholar
  16. 16.
    Beck AT, Weissman A, Lester D, Trexler L: The measure of pessimism: The Hopelessness Scale. J Consult Clin Psychol 42: 861–865, 1974.PubMedCrossRefGoogle Scholar
  17. 17.
    Andreasen NC: Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 39: 784–788, 1982.PubMedCrossRefGoogle Scholar
  18. 18.
    Seitz R: Five psychological measures of neurotic depression: A correlation study. J Clin Psychol 26: 504–505, 1970.PubMedCrossRefGoogle Scholar
  19. 19.
    Turner JA, Romano JM: Self-report screening measures for depression in chronic pain patients. J Clin Psychol 40: 909–913, 1984.PubMedCrossRefGoogle Scholar
  20. 20.
    Holland TR, Levi M, Watson CG: MMPI basic scales vs. two-point codes in the discrimination of psychopathological groups. J Clin Psychol 37: 394–396, 1981.PubMedGoogle Scholar
  21. 21.
    Rosen A: Differentiation of diagnostic groups by individual MMPI scales. J Consult Psychol 22: 453–457, 1958.PubMedCrossRefGoogle Scholar
  22. 22.
    Dalby JT, Williams R: Depression in schizophrenia: The influence of intelligence. Can J Psychiatry 32: 816–817, 1987.PubMedGoogle Scholar
  23. 23.
    Walters GD: The MMPI and schizophrenia: A review. Schizoph Bull 9: 226–246, 1983.PubMedCrossRefGoogle Scholar
  24. 24.
    Kleinke CL: Comparing depression-coping strategies of schizophrenic men and depressed and non-depressed college students. J Clin Psychol 40: 420–426, 1984.PubMedCrossRefGoogle Scholar
  25. 25.
    Johnson DAW: Studies of depressive symptoms in schizophrenia I. The prevalence of depression and its possible causes. Br J Psychiatry 139: 89–101, 1981.PubMedCrossRefGoogle Scholar
  26. 26.
    Leff J, Tress K, Edwards B: The clinical course of depressive symptoms in schizophrenia. Schizophrenia Research 1: 25–30, 1988.PubMedCrossRefGoogle Scholar
  27. 27.
    Rush AJ, Khatami M, Beck AT: Cognitive and behavior therapy in chronic depression. Behavior Therapy 6: 398–404, 1975.CrossRefGoogle Scholar
  28. 28.
    Siris SG, Strahan A, Mendeli J, Cooper TB, Casey E: Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression. Schizophrenia Research 1: 31–35, 1988.PubMedCrossRefGoogle Scholar
  29. 29.
    Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79–91, 1988.PubMedCrossRefGoogle Scholar
  30. 30.
    Schneier FR, Siris SG: A review of psychoactive substance use and abuse in schizophrenia: Patterns of drug choice. J Nery Ment Dis 175: 641–652, 1987.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Richard Williams
    • 1
  • J. Thomas Dalby
    • 1
  1. 1.Departments of Psychiatry and PsychologyCalgary General Hospital and University of CalgaryCalgaryUSA

Personalised recommendations